School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Department of Cardiology, Middlemore Hospital, Auckland, New Zealand.
Lancet. 2021 Jun 12;397(10291):2264-2274. doi: 10.1016/S0140-6736(21)00572-9. Epub 2021 Jun 2.
Until recently, most patients with diabetes worldwide have been diagnosed when symptomatic and have high cardiovascular risk, meaning most should be prescribed cardiovascular preventive medications. However, in New Zealand, a world-first national programme led to approximately 90% of eligible adults being screened for diabetes by 2016, up from 50% in 2012, identifying many asymptomatic patients with recent-onset diabetes. We hypothesised that cardiovascular risk prediction equations derived before widespread screening would now significantly overestimate risk in screen-detected patients.
New Zealanders aged 30-74 years with type 2 diabetes and without known cardiovascular disease, heart failure, or substantial renal impairment were identified from the 400 000-person PREDICT primary care cohort study between Oct 27, 2004, and Dec 30, 2016, covering the period before and after widespread screening. Sex-specific equations estimating 5-year risk of cardiovascular disease were developed using Cox regression models, with 18 prespecified predictors, including diabetes-related and renal function measures. Equation performance was compared with an equivalent equation derived in the New Zealand Diabetes Cohort Study (NZDCS), which recruited between 2000 and 2006, before widespread screening.
46 652 participants were included in the PREDICT-1° Diabetes subcohort, of whom 4114 experienced first cardiovascular events during follow-up (median 5·2 years, IQR 3·3-7·4). 14 829 (31·8%) were not taking oral hypoglycaemic medications or insulin at baseline. Median 5-year cardiovascular risk estimated by the new equations was 4·0% (IQR 2·3-6·8) in women and 7·1% (4·5-11·2) in men. The older NZDCS equation overestimated median cardiovascular risk by three times in women (median 14·2% [9·7-20·0]) and two times in men (17·1% [4·5-20·0]). Model and discrimination performance measures for PREDICT-1° Diabetse equations were also significantly better than for the NZDCS equation (eg, for women: R=32% [95% CI 29-34], Harrell's C=0·73 [0·72-0·74], Royston's D=1·410 [1·330-1·490] vs R=24% [21-26], C=0·69 [0·67-0·70], and D=1·147 [1·107-1·187]).
International treatment guidelines still consider most people with diabetes to be at high cardiovascular risk; however, we show that recent widespread diabetes screening has radically changed the cardiovascular risk profile of people with diabetes in New Zealand. Many of these patients have normal renal function, are not dispensed glucose-lowering medications, and have low cardiovascular risk. These findings have clear international implications as increased diabetes screening is inevitable due to increasing obesity, simpler screening tests, and the introduction of new-generation glucose-lowering medications that prevent cardiovascular events. Cardiovascular risk prediction equations derived from contemporary diabetes populations, with multiple diabetes-related and renal function predictors, will be required to better differentiate between low-risk and high-risk patients in this increasingly heterogeneous population and to inform appropriate non-pharmacological management and cost-effective targeting of expensive new medications.
Health Research Council of New Zealand, Heart Foundation of New Zealand, and Healthier Lives National Science Challenge.
直到最近,全球大多数糖尿病患者都是在出现症状且具有较高心血管风险时才被诊断出来的,这意味着大多数患者都应该开具有心血管预防作用的药物。然而,在新西兰,一个世界首创的全国性项目使符合条件的成年人中大约有 90%在 2016 年之前接受了糖尿病筛查,而在 2012 年这一比例仅为 50%。这一项目发现了许多无症状的新发糖尿病患者。我们假设,在广泛筛查之前得出的心血管风险预测方程现在会显著高估筛查出的患者的风险。
从 2004 年 10 月 27 日至 2016 年 12 月 30 日期间的 PREDICT 初级保健队列研究的 40 万人群中,确定了新西兰年龄在 30-74 岁之间、患有 2 型糖尿病且无已知心血管疾病、心力衰竭或严重肾功能不全的人群。使用 Cox 回归模型开发了估计心血管疾病 5 年风险的性别特异性方程,其中包含 18 个预设预测因素,包括与糖尿病相关的和肾功能的指标。通过与在新西兰糖尿病队列研究(NZDCS)中得出的等效方程进行比较来评估方程的性能,NZDCS 招募时间为 2000 年至 2006 年,处于广泛筛查之前。
在 PREDICT-1°糖尿病亚队列中,有 46652 名参与者纳入研究,其中 4114 名在随访期间发生了首次心血管事件(中位随访时间为 5.2 年,IQR 3.3-7.4)。在基线时,有 14829 人(31.8%)未服用口服降糖药物或胰岛素。新方程估计的中位 5 年心血管风险在女性中为 4.0%(IQR 2.3-6.8),在男性中为 7.1%(4.5-11.2)。在女性中,旧的 NZDCS 方程高估了中位心血管风险三倍(中位数 14.2%[9.7-20.0]),在男性中高估了两倍(17.1%[4.5-20.0])。对于 PREDICT-1°糖尿病方程,模型和判别性能测量指标也明显优于 NZDCS 方程(例如,对于女性:R=32%[95%CI 29-34],Harrell's C=0.73[0.72-0.74],Royston's D=1.410[1.330-1.490] vs R=24%[21-26],C=0.69[0.67-0.70],D=1.147[1.107-1.187])。
国际治疗指南仍然认为大多数糖尿病患者具有较高的心血管风险;然而,我们发现最近广泛的糖尿病筛查已经彻底改变了新西兰糖尿病患者的心血管风险状况。这些患者中的许多人肾功能正常,未使用降血糖药物,且心血管风险较低。这些发现具有明确的国际意义,因为随着肥胖的增加、更简单的筛查测试以及新一代预防心血管事件的降血糖药物的推出,糖尿病筛查的增加是不可避免的。为了更好地区分低风险和高风险患者,并为这一日益多样化的人群提供适当的非药物管理和具有成本效益的昂贵新型药物的靶向治疗,需要使用包含多种糖尿病相关和肾功能指标的当代糖尿病人群得出的心血管风险预测方程。
新西兰健康研究理事会、新西兰心脏基金会和健康生活国家科学挑战。